Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.

[1]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[2]  C. White,et al.  Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. , 1997, The Journal of biological chemistry.

[3]  W. El-Deiry.  Role of oncogenes in resistance and killing by cancer therapeutic agents. , 1997, Current opinion in oncology.

[4]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[5]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[6]  G. van Kaick,et al.  New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification , 1992, Cancer.

[7]  F. Uckun,et al.  Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target , 1999 .

[8]  Y F Hui,et al.  Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  A. Israël,et al.  IκB proteins: structure, function and regulation , 1997 .

[10]  M. Ranson,et al.  Chemotherapy in non-small cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  David Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.

[12]  Matthias Mann,et al.  IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .

[13]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[14]  F. Uckun,et al.  Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. , 1998, Biochemical pharmacology.

[15]  J. Christman,et al.  The role of nuclear factor-kappa B in cytokine gene regulation. , 1997, American journal of respiratory cell and molecular biology.

[16]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[17]  K. Kelly,et al.  New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  W. Sellers,et al.  Apoptosis and cancer drug targeting. , 1999, The Journal of clinical investigation.

[19]  D. Brenner,et al.  I κ B α Gene Transfer Is Cytotoxic to Squamous-Cell Lung Cancer Cells and Sensitizes Them to Tumor Necrosis Factor- α –Mediated Cell Death , 1999 .

[20]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[21]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[22]  T. McKinsey,et al.  Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation , 1995, Molecular and cellular biology.

[23]  Marty W. Mayo,et al.  NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.

[24]  C. Y. Wang,et al.  Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.

[25]  J. Roth,et al.  Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. , 1995, Oncogene.